| Miss Jessica B Windschitl, DO | |
|
1532 W 32nd St Ste 301, Joplin, MO 64804-1639 | |
| (417) 347-2525 | |
| (417) 347-8991 |
| Full Name | Miss Jessica B Windschitl |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 1532 W 32nd St Ste 301, Joplin, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427440619 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 2019026485 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Freeman Health System - Freeman West | Joplin, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Freeman-oak Hill Health System | 8325942253 | 316 |
News Archive
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
People with arthritis who exercise have less pain, more energy, improved sleep, and better day-to-day function, according to the American College of Rheumatology.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series
› Verified 3 days ago
| Entity Name | Mercy Clinic Springfield Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245277631 PECOS PAC ID: 7416865845 Enrollment ID: O20031104000060 |
News Archive
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
People with arthritis who exercise have less pain, more energy, improved sleep, and better day-to-day function, according to the American College of Rheumatology.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series
› Verified 3 days ago
| Entity Name | Freeman-oak Hill Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679517023 PECOS PAC ID: 8325942253 Enrollment ID: O20040218000570 |
News Archive
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
People with arthritis who exercise have less pain, more energy, improved sleep, and better day-to-day function, according to the American College of Rheumatology.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series
› Verified 3 days ago
| Entity Name | Ozark Tri-county Health Care Consortium |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265428791 PECOS PAC ID: 8123918257 Enrollment ID: O20040330001501 |
News Archive
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
People with arthritis who exercise have less pain, more energy, improved sleep, and better day-to-day function, according to the American College of Rheumatology.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Jessica B Windschitl, DO Po Box 3810, Joplin, MO 64803-3810 Ph: (417) 347-2525 | Miss Jessica B Windschitl, DO 1532 W 32nd St Ste 301, Joplin, MO 64804-1639 Ph: (417) 347-2525 |
News Archive
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
People with arthritis who exercise have less pain, more energy, improved sleep, and better day-to-day function, according to the American College of Rheumatology.
So disease-causing bacteria in the body finally have multiplied to the point where their numbers are large enough to cause illness. What's next? They get out their "smart phones" and whisper "Let's roll!" That's how an article in ACS' monthly Chemical Reviews describes the substances "smart phones of the microbial world" that bacteria use to transmit chemical signals that launch infections and monitor their environment.
Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series
› Verified 3 days ago
Jeffrey Cox, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1532 W 32nd St, Ste 201, Joplin, MO 64804 Phone: 417-347-8660 Fax: 417-347-8691 | |
Oman E Dement, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1532 W 32nd St, Ste 401, Joplin, MO 64804 Phone: 417-347-7009 Fax: 417-347-3288 | |
Cheryl A Fogarty, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 3103 Mcclelland Blvd, Joplin, MO 64804 Phone: 417-624-2621 Fax: 417-624-4652 | |
Dr. Terry Keith Grebe, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 2736 E 15th St, Joplin, MO 64804 Phone: 417-782-0166 Fax: 417-782-0166 | |
Christopher H. Roberts, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2216 E 32nd St Ste 101, Joplin, MO 64804 Phone: 417-622-0911 Fax: 417-622-0730 | |
Jack Tyrone Adcock, DO Obstetrics & Gynecology Medicare: May Accept Medicare Assignments Practice Location: 3401 Mcintosh Cir Ste 200, Joplin, MO 64804 Phone: 417-347-3703 Fax: 417-347-3727 |